Loading…
The potential utility of [68 Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent—comparison with [18F]FDG
Purpose This study aimed to compare the detection performance of [ 68 Ga]Ga-DOTA-FAPI-04 and [ 18 F]FDG PET/CT in the patients with various oncological and non-oncological lesions. Methods A total of 123 patients underwent contemporaneous [ 68 Ga]Ga-DOTA-FAPI-04 and [ 18 F]FDG PET/CT were included...
Saved in:
| Published in: | European journal of nuclear medicine and molecular imaging 2022-02, Vol.49 (3), p.963-979 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c419t-da9f07695fbef356407a6c817f39be20515095a7dbcc7a4fb3398572265ac68d3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c419t-da9f07695fbef356407a6c817f39be20515095a7dbcc7a4fb3398572265ac68d3 |
| container_end_page | 979 |
| container_issue | 3 |
| container_start_page | 963 |
| container_title | European journal of nuclear medicine and molecular imaging |
| container_volume | 49 |
| creator | Lan, Lianjun Liu, Hanxiang Wang, Yingwei Deng, Jia Peng, Dengsai Feng, Yue Wang, Li Chen, Yue Qiu, Lin |
| description | Purpose
This study aimed to compare the detection performance of [
68
Ga]Ga-DOTA-FAPI-04 and [
18
F]FDG PET/CT in the patients with various oncological and non-oncological lesions.
Methods
A total of 123 patients underwent contemporaneous [
68
Ga]Ga-DOTA-FAPI-04 and [
18
F]FDG PET/CT were included in this prospective study. The maximum standard uptake value (SUVmax) was measured to compare oncological and non-oncological lesion uptake. The sensitivity, specificity, predictive values, and accuracy of [
18
F]FDG and [
68
Ga]Ga-DOTA-FAPI-04 PET/CT for detecting primary, metastatic, and non-oncological lesions were calculated and compared to evaluate the detection efficacy.
Results
The study subjects consisted of 123 patients (69 men and 54 women; mean age 56.11 ± 11.94 years). Among the 102 patients with either newly diagnosed (82 patients) or previously treated solid tumor (20 patients), a total of 88 solid primary malignant tumors in 84/102 patients were detected. Two patients had two primary tumors each and 1 patient had three primary tumors. Among them, 58/102 and 43/102 patients had nodal (376 lesions) and distant metastases (406 lesions), respectively. Eight patients had hematological neoplasm. No malignant oncological diseases were detected in the remaining 13 patients. A total of 145 non-oncological lesions and benign tumors in 52/123 patients were detected incidentally. [
68
Ga]Ga-DOTA-FAPI-04 PET/CT demonstrated a significantly higher uptake and detection rate for the primary (SUVmax 10.98 ± 5.83 vs. 8.36 ± 6.43,
p
|
| doi_str_mv | 10.1007/s00259-021-05522-w |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2562829881</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2562829881</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-da9f07695fbef356407a6c817f39be20515095a7dbcc7a4fb3398572265ac68d3</originalsourceid><addsrcrecordid>eNp9kUFu1DAUhiMEoqVwARbIEhs2hmfHju3lqGWGSpXKYlhVleU4TpoqsYOddNQdd4ADcBaOwkkwTCmIBSs_2d_7n5--onhO4DUBEG8SAOUKAyUYOKcU7x4Uh6QiCguQ6uF9LeCgeJLSNQCRVKrHxUHJGAFW8sPi8_bKoSnMzs-9GdAy90M_36LQootKfvu6MZcbg0_Otyu8Xr0_xcCQScggH27cgOoYTIPT5OwclxEFb8MQut7mIOObDHn8910_mq73HTJdnvb90xcbxsnEPgWPdv18hS6IXF-uTzZPi0etGZJ7dnceFR_Wb7fH7_DZ-eb0eHWGLSNqxo1RLYhK8bZ2bckrBsJUVhLRlqp2FDjhoLgRTW2tMKyty1JJLiituLGVbMqj4tU-d4rh4-LSrMc-WTcMxruwJE15RSVVUpKMvvwHvQ5L9Pl3mlaUQcm4Ypmie8rGkFJ0rZ5iXjreagL6pzK9V6azMv1Lmd7lphd30Us9uua-5bejDJR7IOUn37n4Z_Z_Yn8AKsWiog</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2624034594</pqid></control><display><type>article</type><title>The potential utility of [68 Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent—comparison with [18F]FDG</title><source>Springer Nature</source><creator>Lan, Lianjun ; Liu, Hanxiang ; Wang, Yingwei ; Deng, Jia ; Peng, Dengsai ; Feng, Yue ; Wang, Li ; Chen, Yue ; Qiu, Lin</creator><creatorcontrib>Lan, Lianjun ; Liu, Hanxiang ; Wang, Yingwei ; Deng, Jia ; Peng, Dengsai ; Feng, Yue ; Wang, Li ; Chen, Yue ; Qiu, Lin</creatorcontrib><description><![CDATA[Purpose
This study aimed to compare the detection performance of [
68
Ga]Ga-DOTA-FAPI-04 and [
18
F]FDG PET/CT in the patients with various oncological and non-oncological lesions.
Methods
A total of 123 patients underwent contemporaneous [
68
Ga]Ga-DOTA-FAPI-04 and [
18
F]FDG PET/CT were included in this prospective study. The maximum standard uptake value (SUVmax) was measured to compare oncological and non-oncological lesion uptake. The sensitivity, specificity, predictive values, and accuracy of [
18
F]FDG and [
68
Ga]Ga-DOTA-FAPI-04 PET/CT for detecting primary, metastatic, and non-oncological lesions were calculated and compared to evaluate the detection efficacy.
Results
The study subjects consisted of 123 patients (69 men and 54 women; mean age 56.11 ± 11.94 years). Among the 102 patients with either newly diagnosed (82 patients) or previously treated solid tumor (20 patients), a total of 88 solid primary malignant tumors in 84/102 patients were detected. Two patients had two primary tumors each and 1 patient had three primary tumors. Among them, 58/102 and 43/102 patients had nodal (376 lesions) and distant metastases (406 lesions), respectively. Eight patients had hematological neoplasm. No malignant oncological diseases were detected in the remaining 13 patients. A total of 145 non-oncological lesions and benign tumors in 52/123 patients were detected incidentally. [
68
Ga]Ga-DOTA-FAPI-04 PET/CT demonstrated a significantly higher uptake and detection rate for the primary (SUVmax 10.98 ± 5.83 vs. 8.36 ± 6.43,
p
< 0.001; sensitivity 97.67 vs. 84.89%; and accuracy 96.59 vs. 82.95%,
X
2
= 0.538,
p
= 0.021), nodal (SUVmax 10.50 ± 5.98 vs. 8.20 ± 6.29,
p
= 0.011; sensitivity 97.59 vs. 84.72%; and accuracy 97.34 vs. 84.31%,
X
2
= 2.067,
p
< 0.001), and distant metastatic lesions (SUVmax 9.64 ± 6.45 vs. 6.74 ± 4.83;
p
< 0.001; sensitivity 98.01 vs. 65.59%; and accuracy 97.04 vs. 65.51%,
X
2
= 4.897,
p
< 0.001) of solid tumor than did [
18
F]FDG PET/CT. [
68
Ga]Ga-DOTA-FAPI-04 PET/CT demonstrated a lower activity (SUVmax: 6.84 ± 4.67
vs.
13.09 ± 7.29,
p
< 0.001) and detection rate (sensitivity 50.65 vs. 96.75%, and accuracy 51.28 vs. 95.51%,
X
2
= 5.166,
p
< 0.001) for multiple myeloma and lymphoma compared to [
18
F]FDG PET/CT. [
68
Ga]Ga-DOTA-FAPI-04 and [
18
F]FDG PET/CT PET/CT demonstrated a comparative activity (SUVmax 6.40 ± 3.95 vs. 5.74 ± 15.78,
p
= 0.729) and detection efficacy (sensitivity 86.52 vs. 72.34%, and accuracy 84.83 vs. 72.41%,
X
2
= 9.460,
p
= 0.007) for non-oncological lesion and benign tumor detection.
Conclusions
Except for myeloma and lymphoma, [
68
Ga]Ga-DOTA-FAPI-04 PET/CT showed a superior detection efficacy for detecting various primary and metastatic lesions than [
18
F]FDG PET/CT. A comparative detection utility for non-oncological lesion was obtained with both tracers. [
68
Ga]Ga-DOTA-FAPI-04 could be used as a broad-spectrum tumor and inflammatory imaging agent in the clinical especially for various solid tumors and non-oncological lesions.]]></description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-021-05522-w</identifier><identifier>PMID: 34410435</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Accuracy ; Adult ; Aged ; Cardiology ; Computed tomography ; Female ; Fluorine isotopes ; Fluorodeoxyglucose F18 ; Gallium Radioisotopes ; Heterocyclic Compounds, 1-Ring ; Humans ; Imaging ; Inflammation ; Lesions ; Lymphoma ; Male ; Medical imaging ; Medicine ; Medicine & Public Health ; Metastases ; Metastasis ; Middle Aged ; Multiple Myeloma ; Nuclear Medicine ; Oncology ; Oncology – General ; Original Article ; Orthopedics ; Patients ; Positron emission ; Positron emission tomography ; Positron Emission Tomography Computed Tomography ; Prospective Studies ; Quinolines ; Radiology ; Sensitivity ; Solid tumors ; Tomography ; Tumors</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2022-02, Vol.49 (3), p.963-979</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-da9f07695fbef356407a6c817f39be20515095a7dbcc7a4fb3398572265ac68d3</citedby><cites>FETCH-LOGICAL-c419t-da9f07695fbef356407a6c817f39be20515095a7dbcc7a4fb3398572265ac68d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27911,27912</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34410435$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lan, Lianjun</creatorcontrib><creatorcontrib>Liu, Hanxiang</creatorcontrib><creatorcontrib>Wang, Yingwei</creatorcontrib><creatorcontrib>Deng, Jia</creatorcontrib><creatorcontrib>Peng, Dengsai</creatorcontrib><creatorcontrib>Feng, Yue</creatorcontrib><creatorcontrib>Wang, Li</creatorcontrib><creatorcontrib>Chen, Yue</creatorcontrib><creatorcontrib>Qiu, Lin</creatorcontrib><title>The potential utility of [68 Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent—comparison with [18F]FDG</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description><![CDATA[Purpose
This study aimed to compare the detection performance of [
68
Ga]Ga-DOTA-FAPI-04 and [
18
F]FDG PET/CT in the patients with various oncological and non-oncological lesions.
Methods
A total of 123 patients underwent contemporaneous [
68
Ga]Ga-DOTA-FAPI-04 and [
18
F]FDG PET/CT were included in this prospective study. The maximum standard uptake value (SUVmax) was measured to compare oncological and non-oncological lesion uptake. The sensitivity, specificity, predictive values, and accuracy of [
18
F]FDG and [
68
Ga]Ga-DOTA-FAPI-04 PET/CT for detecting primary, metastatic, and non-oncological lesions were calculated and compared to evaluate the detection efficacy.
Results
The study subjects consisted of 123 patients (69 men and 54 women; mean age 56.11 ± 11.94 years). Among the 102 patients with either newly diagnosed (82 patients) or previously treated solid tumor (20 patients), a total of 88 solid primary malignant tumors in 84/102 patients were detected. Two patients had two primary tumors each and 1 patient had three primary tumors. Among them, 58/102 and 43/102 patients had nodal (376 lesions) and distant metastases (406 lesions), respectively. Eight patients had hematological neoplasm. No malignant oncological diseases were detected in the remaining 13 patients. A total of 145 non-oncological lesions and benign tumors in 52/123 patients were detected incidentally. [
68
Ga]Ga-DOTA-FAPI-04 PET/CT demonstrated a significantly higher uptake and detection rate for the primary (SUVmax 10.98 ± 5.83 vs. 8.36 ± 6.43,
p
< 0.001; sensitivity 97.67 vs. 84.89%; and accuracy 96.59 vs. 82.95%,
X
2
= 0.538,
p
= 0.021), nodal (SUVmax 10.50 ± 5.98 vs. 8.20 ± 6.29,
p
= 0.011; sensitivity 97.59 vs. 84.72%; and accuracy 97.34 vs. 84.31%,
X
2
= 2.067,
p
< 0.001), and distant metastatic lesions (SUVmax 9.64 ± 6.45 vs. 6.74 ± 4.83;
p
< 0.001; sensitivity 98.01 vs. 65.59%; and accuracy 97.04 vs. 65.51%,
X
2
= 4.897,
p
< 0.001) of solid tumor than did [
18
F]FDG PET/CT. [
68
Ga]Ga-DOTA-FAPI-04 PET/CT demonstrated a lower activity (SUVmax: 6.84 ± 4.67
vs.
13.09 ± 7.29,
p
< 0.001) and detection rate (sensitivity 50.65 vs. 96.75%, and accuracy 51.28 vs. 95.51%,
X
2
= 5.166,
p
< 0.001) for multiple myeloma and lymphoma compared to [
18
F]FDG PET/CT. [
68
Ga]Ga-DOTA-FAPI-04 and [
18
F]FDG PET/CT PET/CT demonstrated a comparative activity (SUVmax 6.40 ± 3.95 vs. 5.74 ± 15.78,
p
= 0.729) and detection efficacy (sensitivity 86.52 vs. 72.34%, and accuracy 84.83 vs. 72.41%,
X
2
= 9.460,
p
= 0.007) for non-oncological lesion and benign tumor detection.
Conclusions
Except for myeloma and lymphoma, [
68
Ga]Ga-DOTA-FAPI-04 PET/CT showed a superior detection efficacy for detecting various primary and metastatic lesions than [
18
F]FDG PET/CT. A comparative detection utility for non-oncological lesion was obtained with both tracers. [
68
Ga]Ga-DOTA-FAPI-04 could be used as a broad-spectrum tumor and inflammatory imaging agent in the clinical especially for various solid tumors and non-oncological lesions.]]></description><subject>Accuracy</subject><subject>Adult</subject><subject>Aged</subject><subject>Cardiology</subject><subject>Computed tomography</subject><subject>Female</subject><subject>Fluorine isotopes</subject><subject>Fluorodeoxyglucose F18</subject><subject>Gallium Radioisotopes</subject><subject>Heterocyclic Compounds, 1-Ring</subject><subject>Humans</subject><subject>Imaging</subject><subject>Inflammation</subject><subject>Lesions</subject><subject>Lymphoma</subject><subject>Male</subject><subject>Medical imaging</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Multiple Myeloma</subject><subject>Nuclear Medicine</subject><subject>Oncology</subject><subject>Oncology – General</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Patients</subject><subject>Positron emission</subject><subject>Positron emission tomography</subject><subject>Positron Emission Tomography Computed Tomography</subject><subject>Prospective Studies</subject><subject>Quinolines</subject><subject>Radiology</subject><subject>Sensitivity</subject><subject>Solid tumors</subject><subject>Tomography</subject><subject>Tumors</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kUFu1DAUhiMEoqVwARbIEhs2hmfHju3lqGWGSpXKYlhVleU4TpoqsYOddNQdd4ADcBaOwkkwTCmIBSs_2d_7n5--onhO4DUBEG8SAOUKAyUYOKcU7x4Uh6QiCguQ6uF9LeCgeJLSNQCRVKrHxUHJGAFW8sPi8_bKoSnMzs-9GdAy90M_36LQootKfvu6MZcbg0_Otyu8Xr0_xcCQScggH27cgOoYTIPT5OwclxEFb8MQut7mIOObDHn8910_mq73HTJdnvb90xcbxsnEPgWPdv18hS6IXF-uTzZPi0etGZJ7dnceFR_Wb7fH7_DZ-eb0eHWGLSNqxo1RLYhK8bZ2bckrBsJUVhLRlqp2FDjhoLgRTW2tMKyty1JJLiituLGVbMqj4tU-d4rh4-LSrMc-WTcMxruwJE15RSVVUpKMvvwHvQ5L9Pl3mlaUQcm4Ypmie8rGkFJ0rZ5iXjreagL6pzK9V6azMv1Lmd7lphd30Us9uua-5bejDJR7IOUn37n4Z_Z_Yn8AKsWiog</recordid><startdate>20220201</startdate><enddate>20220201</enddate><creator>Lan, Lianjun</creator><creator>Liu, Hanxiang</creator><creator>Wang, Yingwei</creator><creator>Deng, Jia</creator><creator>Peng, Dengsai</creator><creator>Feng, Yue</creator><creator>Wang, Li</creator><creator>Chen, Yue</creator><creator>Qiu, Lin</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20220201</creationdate><title>The potential utility of [68 Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent—comparison with [18F]FDG</title><author>Lan, Lianjun ; Liu, Hanxiang ; Wang, Yingwei ; Deng, Jia ; Peng, Dengsai ; Feng, Yue ; Wang, Li ; Chen, Yue ; Qiu, Lin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-da9f07695fbef356407a6c817f39be20515095a7dbcc7a4fb3398572265ac68d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Accuracy</topic><topic>Adult</topic><topic>Aged</topic><topic>Cardiology</topic><topic>Computed tomography</topic><topic>Female</topic><topic>Fluorine isotopes</topic><topic>Fluorodeoxyglucose F18</topic><topic>Gallium Radioisotopes</topic><topic>Heterocyclic Compounds, 1-Ring</topic><topic>Humans</topic><topic>Imaging</topic><topic>Inflammation</topic><topic>Lesions</topic><topic>Lymphoma</topic><topic>Male</topic><topic>Medical imaging</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Multiple Myeloma</topic><topic>Nuclear Medicine</topic><topic>Oncology</topic><topic>Oncology – General</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Patients</topic><topic>Positron emission</topic><topic>Positron emission tomography</topic><topic>Positron Emission Tomography Computed Tomography</topic><topic>Prospective Studies</topic><topic>Quinolines</topic><topic>Radiology</topic><topic>Sensitivity</topic><topic>Solid tumors</topic><topic>Tomography</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lan, Lianjun</creatorcontrib><creatorcontrib>Liu, Hanxiang</creatorcontrib><creatorcontrib>Wang, Yingwei</creatorcontrib><creatorcontrib>Deng, Jia</creatorcontrib><creatorcontrib>Peng, Dengsai</creatorcontrib><creatorcontrib>Feng, Yue</creatorcontrib><creatorcontrib>Wang, Li</creatorcontrib><creatorcontrib>Chen, Yue</creatorcontrib><creatorcontrib>Qiu, Lin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Source (ProQuest)</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Biological Science Journals</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest advanced technologies & aerospace journals</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lan, Lianjun</au><au>Liu, Hanxiang</au><au>Wang, Yingwei</au><au>Deng, Jia</au><au>Peng, Dengsai</au><au>Feng, Yue</au><au>Wang, Li</au><au>Chen, Yue</au><au>Qiu, Lin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The potential utility of [68 Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent—comparison with [18F]FDG</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><stitle>Eur J Nucl Med Mol Imaging</stitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><date>2022-02-01</date><risdate>2022</risdate><volume>49</volume><issue>3</issue><spage>963</spage><epage>979</epage><pages>963-979</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract><![CDATA[Purpose
This study aimed to compare the detection performance of [
68
Ga]Ga-DOTA-FAPI-04 and [
18
F]FDG PET/CT in the patients with various oncological and non-oncological lesions.
Methods
A total of 123 patients underwent contemporaneous [
68
Ga]Ga-DOTA-FAPI-04 and [
18
F]FDG PET/CT were included in this prospective study. The maximum standard uptake value (SUVmax) was measured to compare oncological and non-oncological lesion uptake. The sensitivity, specificity, predictive values, and accuracy of [
18
F]FDG and [
68
Ga]Ga-DOTA-FAPI-04 PET/CT for detecting primary, metastatic, and non-oncological lesions were calculated and compared to evaluate the detection efficacy.
Results
The study subjects consisted of 123 patients (69 men and 54 women; mean age 56.11 ± 11.94 years). Among the 102 patients with either newly diagnosed (82 patients) or previously treated solid tumor (20 patients), a total of 88 solid primary malignant tumors in 84/102 patients were detected. Two patients had two primary tumors each and 1 patient had three primary tumors. Among them, 58/102 and 43/102 patients had nodal (376 lesions) and distant metastases (406 lesions), respectively. Eight patients had hematological neoplasm. No malignant oncological diseases were detected in the remaining 13 patients. A total of 145 non-oncological lesions and benign tumors in 52/123 patients were detected incidentally. [
68
Ga]Ga-DOTA-FAPI-04 PET/CT demonstrated a significantly higher uptake and detection rate for the primary (SUVmax 10.98 ± 5.83 vs. 8.36 ± 6.43,
p
< 0.001; sensitivity 97.67 vs. 84.89%; and accuracy 96.59 vs. 82.95%,
X
2
= 0.538,
p
= 0.021), nodal (SUVmax 10.50 ± 5.98 vs. 8.20 ± 6.29,
p
= 0.011; sensitivity 97.59 vs. 84.72%; and accuracy 97.34 vs. 84.31%,
X
2
= 2.067,
p
< 0.001), and distant metastatic lesions (SUVmax 9.64 ± 6.45 vs. 6.74 ± 4.83;
p
< 0.001; sensitivity 98.01 vs. 65.59%; and accuracy 97.04 vs. 65.51%,
X
2
= 4.897,
p
< 0.001) of solid tumor than did [
18
F]FDG PET/CT. [
68
Ga]Ga-DOTA-FAPI-04 PET/CT demonstrated a lower activity (SUVmax: 6.84 ± 4.67
vs.
13.09 ± 7.29,
p
< 0.001) and detection rate (sensitivity 50.65 vs. 96.75%, and accuracy 51.28 vs. 95.51%,
X
2
= 5.166,
p
< 0.001) for multiple myeloma and lymphoma compared to [
18
F]FDG PET/CT. [
68
Ga]Ga-DOTA-FAPI-04 and [
18
F]FDG PET/CT PET/CT demonstrated a comparative activity (SUVmax 6.40 ± 3.95 vs. 5.74 ± 15.78,
p
= 0.729) and detection efficacy (sensitivity 86.52 vs. 72.34%, and accuracy 84.83 vs. 72.41%,
X
2
= 9.460,
p
= 0.007) for non-oncological lesion and benign tumor detection.
Conclusions
Except for myeloma and lymphoma, [
68
Ga]Ga-DOTA-FAPI-04 PET/CT showed a superior detection efficacy for detecting various primary and metastatic lesions than [
18
F]FDG PET/CT. A comparative detection utility for non-oncological lesion was obtained with both tracers. [
68
Ga]Ga-DOTA-FAPI-04 could be used as a broad-spectrum tumor and inflammatory imaging agent in the clinical especially for various solid tumors and non-oncological lesions.]]></abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>34410435</pmid><doi>10.1007/s00259-021-05522-w</doi><tpages>17</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1619-7070 |
| ispartof | European journal of nuclear medicine and molecular imaging, 2022-02, Vol.49 (3), p.963-979 |
| issn | 1619-7070 1619-7089 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2562829881 |
| source | Springer Nature |
| subjects | Accuracy Adult Aged Cardiology Computed tomography Female Fluorine isotopes Fluorodeoxyglucose F18 Gallium Radioisotopes Heterocyclic Compounds, 1-Ring Humans Imaging Inflammation Lesions Lymphoma Male Medical imaging Medicine Medicine & Public Health Metastases Metastasis Middle Aged Multiple Myeloma Nuclear Medicine Oncology Oncology – General Original Article Orthopedics Patients Positron emission Positron emission tomography Positron Emission Tomography Computed Tomography Prospective Studies Quinolines Radiology Sensitivity Solid tumors Tomography Tumors |
| title | The potential utility of [68 Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent—comparison with [18F]FDG |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T04%3A43%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20potential%20utility%20of%20%5B68%C2%A0Ga%5DGa-DOTA-FAPI-04%20as%20a%20novel%20broad-spectrum%20oncological%20and%20non-oncological%20imaging%20agent%E2%80%94comparison%20with%20%5B18F%5DFDG&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Lan,%20Lianjun&rft.date=2022-02-01&rft.volume=49&rft.issue=3&rft.spage=963&rft.epage=979&rft.pages=963-979&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-021-05522-w&rft_dat=%3Cproquest_cross%3E2562829881%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c419t-da9f07695fbef356407a6c817f39be20515095a7dbcc7a4fb3398572265ac68d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2624034594&rft_id=info:pmid/34410435&rfr_iscdi=true |